PN-943
Protagonist Therapeutics, Inc.
['ibd']
no significant difference vs placebo in terms of the primary endpoint; significant differences were noted for endoscopic and histologic improvement at week 12 with the 150 mg dose group #uegweek #ibd #gitwitter 
The Lancet Gastroenterology & Hepatology publishes high-quality peer-reviewed research and reviews, comment, and news #gastroenterology #hepatology. IF=45.042